Equities Analysts Offer Predictions for KALV Q3 Earnings

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Equities research analysts at Leerink Partnrs lifted their Q3 2026 earnings per share estimates for KalVista Pharmaceuticals in a research note issued to investors on Monday, July 7th. Leerink Partnrs analyst J. Schwartz now anticipates that the specialty pharmaceutical company will earn ($0.54) per share for the quarter, up from their prior forecast of ($0.56). The consensus estimate for KalVista Pharmaceuticals' current full-year earnings is ($3.56) per share. Leerink Partnrs also issued estimates for KalVista Pharmaceuticals' Q4 2026 earnings at ($0.42) EPS, FY2026 earnings at ($2.48) EPS and FY2027 earnings at ($1.17) EPS.

Other analysts have also recently issued reports about the stock. Needham & Company LLC restated a "buy" rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. Jones Trading reissued a "buy" rating and set a $30.00 target price on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. JMP Securities boosted their price target on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the company a "market outperform" rating in a report on Tuesday, July 8th. HC Wainwright upped their price target on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. Finally, Leerink Partners lifted their price objective on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an "outperform" rating in a research report on Monday, July 7th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, KalVista Pharmaceuticals has an average rating of "Buy" and a consensus price target of $26.29.

KalVista Pharmaceuticals Trading Down 6.4%

NASDAQ:KALV traded down $0.99 on Thursday, hitting $14.52. 2,085,829 shares of the company's stock traded hands, compared to its average volume of 572,060. The company has a market cap of $725.27 million, a PE ratio of -3.93 and a beta of -0.04. KalVista Pharmaceuticals has a 1 year low of $7.30 and a 1 year high of $16.32. The firm has a 50-day moving average price of $12.57 and a 200-day moving average price of $11.26.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its quarterly earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($2.86). During the same quarter in the previous year, the business earned ($1.07) earnings per share.

Insider Activity at KalVista Pharmaceuticals

In related news, CEO Benjamin L. Palleiko sold 32,979 shares of the company's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $15.69, for a total value of $517,440.51. Following the completion of the sale, the chief executive officer directly owned 369,595 shares in the company, valued at approximately $5,798,945.55. This represents a 8.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Paul K. Audhya sold 2,776 shares of the stock in a transaction on Monday, May 19th. The stock was sold at an average price of $11.84, for a total transaction of $32,867.84. Following the transaction, the insider directly owned 106,611 shares in the company, valued at $1,262,274.24. The trade was a 2.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 48,878 shares of company stock valued at $723,617 over the last three months. Insiders own 10.50% of the company's stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Suvretta Capital Management LLC increased its holdings in shares of KalVista Pharmaceuticals by 16.6% during the 4th quarter. Suvretta Capital Management LLC now owns 4,913,012 shares of the specialty pharmaceutical company's stock valued at $41,613,000 after acquiring an additional 701,007 shares during the last quarter. Tang Capital Management LLC lifted its holdings in KalVista Pharmaceuticals by 13.2% in the 4th quarter. Tang Capital Management LLC now owns 4,893,847 shares of the specialty pharmaceutical company's stock worth $41,451,000 after purchasing an additional 572,300 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its position in KalVista Pharmaceuticals by 32.5% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company's stock worth $41,400,000 after purchasing an additional 1,200,000 shares during the period. Vestal Point Capital LP grew its holdings in KalVista Pharmaceuticals by 19.3% during the fourth quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company's stock valued at $40,402,000 after purchasing an additional 770,000 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in KalVista Pharmaceuticals by 1.9% during the first quarter. Vanguard Group Inc. now owns 2,298,598 shares of the specialty pharmaceutical company's stock valued at $26,526,000 after purchasing an additional 43,355 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).